AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03664986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: The objective of our study is to compare the use of EXPAREL in minimizing post-operative pain after sacrospinous ligament fixation with or without concomitant procedures for pelvic organ prolapse, with or without suburethral sling. We hypothesize that pudendal nerve blockage using long-acting EXPAREL will reduce post-operative pain and potentially reduce oral narcotic consumption. It may also reduce the incidence of postoperative constipation and patient satisfaction.
Study NCT03054974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: modern rehabilitation &Tibetan medicine
Description: modern rehabilitation treatment and Tibetan medicine(medicated bath with wuweiganlu and rub with baimairuangao)
Study NCT04343885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: Patients will be given 7.5GBq of 177Lu-PSMA every 6 weeks for 2 cycles.
Study NCT03867084 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion of Pembrolizumab 200 mg.
Study NCT03867084 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion of 0.9% normal saline.
Study NCT03071302 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EVALUATION OF VSX1, SOD1, and TIMP3 genes
Description: Evaluation of VISX1, SOD1, TIMP3 genes in corneal epithelium, and in peripheral blood. Evaluation of pentacam parameters
Study NCT01237678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMGN901
Description: Phase 2 regimen is IMGN901, Carboplatin, and Etoposide. IMGN901 to be given on days 1 and 8 every 21 days.
Study NCT01237678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin and Etoposide
Description: Patients assigned to Arm 2 were to receive carboplatin at the same AUC as utilized in Arm 1
Study NCT03071302 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: EVALUATION OF VSX1, SOD1, and TIMP3 genes
Description: Evaluation of VISX1, SOD1, TIMP3 genes in corneal epithelium, and in peripheral blood. Evaluation of pentacam parameters
Study NCT04343885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 given every 3 weeks for 6 cycles
Study NCT04343885 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 given every 3 weeks for 6 cycles
Study NCT01328288 — intervention group
Intervention type: DRUG
Intervention: standard ART according to the Thai Ministry of Public Health national guidelines
Description: Patients may receive any of the standard regimens. These regimens are recommended in the Thai Ministry of Public Health National guidelines for the treatment of HIV in children. Change of treatment will be according to the treating physicians.
Study NCT02310958 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic surgical hernia repair
Description: Laparoscopic surgical hernia repair in children
Study NCT03686254 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: RFA, bevacizumab and second-line chemotherapy
Description: Navigated by CT-ultrasound merged images, RFA is taken in the experimental arm at the first day of the first cycle during the second-line therapy. Bevacizumab is given to patients in all arms every 2 weeks (5mg/kg) or 3 weeks (7.5mg/kg), intravenous drip(VD). The second-line chemotherapies include FOLFIRI \[Irinotecan 180 mg/m2 D1+Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1+5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W\] or irinotecan monotherapy (125 mg/m2 D1, 8, q3W or 180 mg/m2 D1, q2W), mFOLFOX6 \[Oxaliplatin 85 mg/m2 D1+Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1+5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W\] or CapeOX (Oxaliplatin 130 mg/m2 D1+Capecitabine 1000 mg/m2 Bid D1-14, q3W)，or irinotecan+oxaliplatin (Oxaliplatin 85 mg/m2 D1+Irinotecan 200 mg/m2 D1, q3W). Among these strategies, the treatment cycle of FOLFIRI, irinotecan monotherapy and mFOLFOX6 is two weeks, while three weeks in CapeOX and irinotecan + oxaliplatin.
Study NCT03686254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab and second-line chemotherapy
Description: Bevacizumab is given to patients in all arms every 2 weeks (5mg/kg) or 3 weeks (7.5mg/kg), intravenous drip(VD). The second-line chemotherapies include FOLFIRI \[Irinotecan 180 mg/m2 D1+Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1+5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W\] or irinotecan monotherapy (125 mg/m2 D1, 8, q3W or 180 mg/m2 D1, q2W), mFOLFOX6 \[Oxaliplatin 85 mg/m2 D1+Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1+5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W\] or CapeOX (Oxaliplatin 130 mg/m2 D1+Capecitabine 1000 mg/m2 Bid D1-14, q3W)，or irinotecan+oxaliplatin (Oxaliplatin 85 mg/m2 D1+Irinotecan 200 mg/m2 D1, q3W). Among these strategies, the treatment cycle of FOLFIRI, irinotecan monotherapy and mFOLFOX6 is two weeks, while three weeks in CapeOX and irinotecan + oxaliplatin.
Study NCT02989636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02989636 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT02989636 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS
Study NCT01020292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Study NCT02974062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar stabilization exercise
Description: Participants were trained using lumbar stabilization exercise based on their initial lumbar stability level. They were received a 30-minute exercise for 1 session in this study.
Study NCT01157871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XRP0038 (NV1FGF)
Description: Pharmaceutical form:solution~Route of administration: intramuscular
Study NCT01157871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Pharmaceutical form:solution~Route of administration: intramuscular
Study NCT02807909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Study NCT01965093 — intervention group
Intervention type: PROCEDURE
Intervention: perioperative desaturation
Description: children aged 0-5 years old who receive general anesthesia and developed perioperative desaturation
Study NCT01965093 — intervention group
Intervention type: PROCEDURE
Intervention: no perioperative desaturation
Description: children aged 0-5 years who did not developed perioperative desaturation under general anesthesia
Study NCT00397254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rizatriptan
Description: 10mg ODT 27 tablets
Study NCT02807909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Study NCT02807909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem ER
Study NCT00397254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rizatriptan
Description: 10mg ODT 9 tablets
Study NCT01217658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Happiest Baby on The Block
Description: Those receiving the intervention will be trained in the infant soothing techniques outlined in The Happiest Baby on the Block.
Study NCT01217658 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AAP Infant Colic counseling
Description: Those receiving the control group allocation will be counseled using the American Academy of Pediatrics material for Infant Colic.
Study NCT02133638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Induction of anesthesia: fentanyl 2 µg kg-1 and a bolus inhalation of 8% sevoflurane in an 8 L.min-1 fresh gas flow. Anesthesia maintenance: 1 minimal alveolar concentration (MAC) sevoflurane at a low fresh gas flow of 0.6-0.8 L min-1 in a 60% air-oxygen mixture supplemented with boluses of fentanyl.
Study NCT02133638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Induction of anesthesia: propofol 2 mg kg-1 and fentanyl 4 µg kg-1. Maintenance of anesthesia: infusion of propofol 8 mg kg-1 h-1 and boluses of fentanyl 3 µg kg-1.
Study NCT00005655 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rh IL-12
Description: rhIL-12 will be administered intravenously on days 2, 4, 6, 10, 12 and 14 of each cycle.
Study NCT00005655 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rh IL-2
Description: rhIL-2 will be administered intravenously every 8 hours x 3 doses on days 1 and 9 of each cycle.
Study NCT03236350 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active autoRIC® (CRIC Treatment)
Description: The active autoRIC® Device is programmed to go through a preset protocol of inflation and deflation cycles every session. The sessions will be repeated daily for 28 days.
Study NCT03236350 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Control autoRIC® (Sham Control)
Description: The Sham Control autoRIC® Device is visually identical to the active autoRIC® Device but the simulated protocol applied comprises of vibrations of the device but no inflation of the cuff every session. The sham device provides the same sound and vibration as that of the pump inflating and the same LED indicators on the Active Unit. The sessions will be repeated daily for 28 days.
Study NCT03934593 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Faith-Based (FB, BHT DSMS)
Description: BHT DSMS Intervention components include Health Sermon and a 6-session Health Bible Study with cooking demonstrations, followed by the Stanford DSMP and a Diabetes Resource Seminar. All intervention activities are implemented by trained church lay leaders.
Study NCT03934593 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Faith-Placed (FP, Stanford DSMP)
Description: Standard Stanford DSMP delivered by health professional
Study NCT02096692 — intervention group
Intervention type: DEVICE
Intervention: Patients with a ProMRI ICD System
Description: Tachycardia Fast Heart Beat
Study NCT02107391 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cells DCVAC/PCa
Description: Combination therapy with DCVAC/PCA add on to and Standard of Care Hormone Therapy
Study NCT02107391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide acetate
Description: Standard of Care Hormone Therapy as an Active Comparator
Study NCT02107391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin Acetate
Description: Standard of Care Hormone Therapy as an Active Comparator
Study NCT02238405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive anti-smoking counseling
Description: Study participants randomized to the intervention arm will receive intensive cessation support outside of the TB clinic setting, from a health worker trained in cessation counseling, during the course of their TB treatment. Behavioral elements will consist of follow up using unscheduled drop in or phone sessions, motivational interviewing, and counseling tailored to the needs and circumstances of the patient. Patients who are current smokers and are ready to commit to quit smoking will be supported to stop completely. Recent smokers will supported for having quit, and the counselor will discuss coping strategies to maintain abstinence.
Study NCT02416687 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implanon®
Description: Postpartum women into whom the etonogestrel-releasing contraceptive implant was inserted in the first 48 h postpartum
Study NCT01629667 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Participants will receive Tralokinumab 400 mg IV infusion Q4W for 68 Weeks.
Study NCT01629667 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Participants will receive Tralokinumab 800 mg IV infusion Q4W for 68 Weeks.
Study NCT02096692 — intervention group
Intervention type: OTHER
Intervention: Magnetic Resonance Imaging (MRI) scan
Description: MRI scan of heart/chest or thoracic spine
Study NCT01652638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Whereas it will be a crossover study with two periods, each drug will be administered only once, at a dose of 5.000UI. In each period, the drug will be administered subcutaneously.
Study NCT02587143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethyl chloride
Description: Nurses will administrate ethyl chloride vapocoolant spray on patient's skin a few seconds before arterial puncture (of cubital arteria).
Study NCT02587143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol
Description: Nurses will use an alcohol-based spray as placebo on patient's skin a few seconds before arterial puncture (of cubital arteria).
Study NCT01629667 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo IV once every 4 Weeks (Q4W) for 68 Weeks.
Study NCT04098952 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 1: Manual Therapy
Description: The treatment techniques used will be: ischemic compression in the trigger point of the masseter and soft-tissue release technique over the temporal region.
Study NCT04098952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 2: Interferential massage plus Manual Therapy
Description: In addition to the treatment techniques applied to the other group, an electric massage will be performed with interferential currents at the level of the cervical region.
Study NCT00668343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: 40 mg/ day
Study NCT00668343 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 80 mg /day
Study NCT02137772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir
Description: Letermovir 240 mg / 480 mg tablets, or 240 mg / 480 mg intravenous solution in 250 mL to be infused over 60 minutes.
Study NCT02137772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, or intravenous solution in 250 mL to be infused over 60 minutes.
Study NCT02986958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-visit patient-family agenda-setting checklist
Description: Pre-visit patient-family agenda-setting checklist
Study NCT02986958 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: routine primary care
Study NCT01266798 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Portal
Description: The portal was tailored to improve the lay public's' healthy skepticism, or in other words, critical and social literacy skills to assist patients in the decision-making process and for improving access to health information and participation. Illustrated by typical examples which can be found in the news and through patient stories, the portal provides an introduction to research methods, the underlying principles of science and critical assessment tools appropriate for a lay public.~1. A checklist for critical assessment of health information~2. Access to research databases for health information and an introduction to research methods and principles of science~3. A checklist to the consultation
Study NCT03348657 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Music Session
Description: Three to four times a week, volunteer musicians came to the geriatric assessment unit and would provide music sessions (duration of about 60 minutes) to the patients who volunteered to attend.
Study NCT02184416 — intervention group
Intervention type: OTHER
Intervention: observational
Description: The study is non interventional. All drugs will be prescribed
Study NCT01825863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Study NCT01825863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 9%
Study NCT02830789 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Study NCT02830789 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium Citrate
Study NCT02830789 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet manufactured to mimic a calcium carbonate tablet
Study NCT02830789 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Description: Roux-en-Y gastric bypass surgery at least 12 months before study inclusion
Study NCT00449852 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response
Description: The IVR group will receive a telephone call from the IVR system three, 14, 30, 90, 120 and 150 days after hospital discharge.
Study NCT02554474 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education, Fitbit/FitViz, physiotherapist counselling.
Description: Participants will receive a brief education session, use a physical activity tracker Fitbit Flex with paired with a FitViz app, and remote counseling by a PT. Intervention will be received immediately.
Study NCT02554474 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Same intervention with a 9-week delay
Description: The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 9-week delay.
Study NCT01949454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorometholone 0.1% ophthalmic solution
Study NCT01949454 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Artificial tears (Placebo)
Description: Artificial tears (Placebo)
Study NCT01821872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of paracetamol
Description: Administration of 1g intravenous paracetamol
Study NCT01398787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B contact lens with color
Description: Plano (-0.00 diopter) silicone hydrogel contact lens in 1 of 4 colors: gray, blue, green, pure hazel
Study NCT01398787 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phemfilcon A contact lens with color
Description: Plano (-0.00 diopter) hydrogel contact lens in 1 of 4 colors: ColorBlends gray, Colorblends blue, Colorblends green, Colorblends pure hazel
Study NCT01228383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies virus-specific monoclonal antibodies
Description: CL184 20 IU/kg intramuscularly on Day 0.
Study NCT01228383 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: human polyclonal rabies immune globulin (HRIG)
Description: HRIG 20 IU/kg intramuscularly on Day 0.
Study NCT01228383 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intramuscularly on Day 0.
Study NCT01228383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human diploid cell vaccine (HDCV)
Description: Rabies vaccine (HDCV) given on Days 0, 3, 7, 14, and 28.
Study NCT01228383 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Human diploid cell vaccine (HDCV)
Description: Rabies vaccine (HDCV) given on Days 0, 3, 7, 14, and 28.
Study NCT01228383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Purified verocell rabies vaccine (PVRV)
Description: Rabies vaccine (PVRV) given on Days 0, 3, 7, 14, and 28.
Study NCT01228383 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Purified verocell rabies vaccine (PVRV)
Description: Rabies vaccine (PVRV) given on Days 0, 3, 7, 14, and 28.
Study NCT01228383 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Purified verocell rabies vaccine (PVRV)
Description: Rabies vaccine (PVRV) given on Days 0, 3, 7, 14, and 28.
Study NCT00696293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Duloxetine up to 120 mg/day + Clinical Management
Study NCT05146011 — intervention group
Intervention type: PROCEDURE
Intervention: Gatsric balloon insertion
Description: Insertion of Gastric balloon prior to laparoscopic gastric bypass surgery
Study NCT03398356 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: for group A: 12 weeks metformin treatment in a final dose 3 x 500 mg~for group B: 3 weeks metformin treatment in a dose 3 x 500 mg, next: 3 weeks metformin treatment in a final dose 3 x 1000mg, next: 3 weeks metformin treatment in a dose 3 x 500 mg.
Study NCT02362113 — intervention group
Intervention type: OTHER
Intervention: GI/GL
Description: GI and GL would be categorized as tertile. due to cross-sectional design of this study, intervention would not be applicable.
Study NCT00740285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% without vessel constrictor
Description: * first 5 days: 20ml lidocaine 2% without vessel constrictor + physiological solution 0,9% 500ml intravenously during 4 hours~* next 5 days: 30ml lidocaine 2% without vessel constrictor + physiological solution 0,9% 500ml intravenously during 4 hours total: 10 days
Study NCT00740285 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - physiological solution 0,9%
Description: first 5 days: 20ml of physiological solution 0,9% 500ml + physiological solution 0,9% 500ml intravenously during 4 hours next 5 days: 30ml of physiological solution 0,9% 500ml + physiological solution 0,9% 500ml intravenously during 4 hours total: 10 days
Study NCT00170235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Exercise class pre-surgery
Study NCT00170235 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Exercise booklet, physiotherapy if needed